The Communication Between the PI3K/AKT/mTOR Pathway and Y-box Binding Protein-1 in Gynecological Cancer

Area of Science:

• Oncology
• Molecular Biology
• Gynecologic Oncology

Background:

• Mechanistic (mammalian) target of rapamycin (mTOR) signaling is implicated in gynecological cancers.
• Elevated mTOR pathway activity correlates with poorer prognosis in these cancers.
• Current mTOR-targeted therapies show limited efficacy in gynecological malignancies.

Purpose of the Study:

• To review recent clinical and basic science findings on the interplay between mTOR signaling and cold shock proteins in gynecological cancers.
• To explore the potential of dual targeting of mTOR and Y-box-protein 1 (YB-1) for improved anti-cancer activity.

Main Methods:

• Literature review of clinical results and basic research.
• Analysis of molecular pathways and protein interactions.

Main Results:

• Dual targeting of mTOR and Y-box-protein 1 (YB-1) demonstrates potential for inhibiting carcinogenic activity.
• Y-box-protein 1 (YB-1) impacts AKT and downstream mTOR interactors like EGFR, Snail, and E-cadherin.
• Several mTOR pathway components are differentially expressed in ovarian, endometrial, and cervical cancers.

Conclusions:

• Y-box-protein 1 (YB-1) is a key player in the mTOR pathway within gynecological cancers.
• Combined targeting of mTOR and YB-1 offers a promising strategy for gynecological cancer treatment.
• Further investigation into downstream actors connecting mTOR and YB-1 is warranted.